AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04641507
Drug: Tadalafil versus tamsulosin as MET
RxNorm normalized name: tamsulosin and tadalafil
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
Trial: NCT04495855
Drug: Dienogest (Visanne,BAY86_5258)
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg (once a day), oral, tablet.
Trial: NCT02033603
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mls of 0.5% ropivacaine
Trial: NCT01367964
Drug: adrenocorticotropin hormone
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 16 units intramuscular injection once daily for 2 weeks
Trial: NCT02679339
Drug: CNTX-2022 (lidocaine gel, 40%)
RxNorm normalized name: lidocaine Topical Gel
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02663284
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine is used to performed the perineural block
Trial: NCT00087750
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01909752
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
Trial: NCT01909752
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
Trial: NCT01814917
Drug: colestilan
RxNorm normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
Trial: NCT01814917
Drug: CBPB
RxNorm normalized name: Carbamazepine-10,11-epoxide
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02009384
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administration of IV ipilimumab for up to 4 cycles
Trial: NCT00403169
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: drug
Trial: NCT01650129
Drug: biphasic insulin aspart 50
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
Trial: NCT01650129
Drug: biphasic human insulin 50
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
Trial: NCT03428477
Drug: Icosapent Ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
Trial: NCT04418479
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period.
Trial: NCT04418479
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period.
Trial: NCT01092832
Drug: voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days.
Trial: NCT02972476
Drug: Budesonide & formoterol fumarate and Aclidinium bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00170573
Drug: Caelyx
RxNorm normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m² biweekly
Trial: NCT02972476
Drug: Fluticasone 500 & salmeterol and Aclidinium bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02972476
Drug: Fluticasone 250 & salmeterol and Aclidinium bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02972476
Drug: Aclidinium bromide & formoterol fumarate
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02346890
Drug: Renvela
RxNorm normalized name: Renvela
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03086642
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL. The second injection up to 4.0 mL of 10\^6, 10\^7, or 10\^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion.
Trial: NCT03725436
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01077375
Drug: Milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~* Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period.
Trial: NCT02793648
Drug: Alpha tocopherol
RxNorm normalized name: alpha tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
Trial: NCT04581824
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
Trial: NCT04581824
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
Trial: NCT02971397
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02971397
Drug: Daunorubicin Hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00653055
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
Trial: NCT00653055
Drug: Dostinex
RxNorm normalized name: Dostinex
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
Trial: NCT01064830
Drug: topical cyclosporine ophthalmic suspension 0.05%
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply 2 drops to 2 target fingernails under occlusion daily
Trial: NCT00413465
Drug: Escherichia Coli Endotoxin
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00800462
Drug: Oxybutynin Cl
RxNorm normalized name: OXYBUTYNIN CL 5MG TAB
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg qd for 3 months
Trial: NCT00800462
Drug: Trospium Cl
RxNorm normalized name: TROSPIUM CL 20MG TAB
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg bid for 3 months
Trial: NCT00800462
Drug: Darifenacin Hydrogen Bromide (HBr)
RxNorm normalized name: Darifenacin Hydrobromide
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 15 mg qd for 3 months
Trial: NCT03720392
Drug: FMT
RxNorm normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
Trial: NCT04545944
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg tablets administered orally
Trial: NCT04545944
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg syrup administered orally
Trial: NCT02325401
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
Trial: NCT02325401
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosed at 100mg/m2 on days 1, 22, and 43
Trial: NCT00871104
Drug: Fosfomycin and imipenem
RxNorm normalized name: imipenem and cilastatin
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
Trial: NCT00599131
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a \< 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, \> 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
Trial: NCT00599131
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
Trial: NCT00599131
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
Trial: NCT00599131
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 by I.V. over one hour on Day # 1 only
Trial: NCT02700087
Drug: ranitidine or famotidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
Trial: NCT00871104
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
Trial: NCT01205997
Drug: magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Trial: NCT00219050
Drug: aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01255852
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
Trial: NCT00529451
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren
Trial: NCT00529451
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparator
Trial: NCT01289821
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
Trial: NCT01289821
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day 1 and day 15 of each cycle, participants will receive 85 mg/m\^2 oxaliplatin as a 2 hour i.v. infusion.
Trial: NCT00593580
Drug: alendronate/cholecalciferol
RxNorm normalized name: ALENDRONATE/CHOLECALCIFEROL
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
Trial: NCT01289821
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2 hour i.v. infusion.
Trial: NCT01289821
Drug: 5-FU (mFOLFOX6)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.
Trial: NCT02013453
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg of Omeprazole will be administered daily by mouth.
Trial: NCT02013453
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered over 30 minutes by continuous infusion.
Trial: NCT02013453
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by infusion.
Trial: NCT02013453
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by infusion.
Trial: NCT00773136
Drug: Bimatoprost Suspension
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: see prior
Trial: NCT00356616
Drug: Trizivir (AZT+3HT+Abacavir) twice daily
RxNorm normalized name: zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trizivir (AZT+3HT+Abacavir) twice daily
Trial: NCT00356616
Drug: Viread (300 mg Tenofovir disoproxil fumarate) once daily
RxNorm normalized name: tenofovir disoproxil fumarate 300 MG [Viread]
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Viread (300 mg Tenofovir disoproxil fumarate) once daily
Trial: NCT04650724
Drug: T cell infusion agent targeting BCMA chimeric antigen receptor
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
Trial: NCT00650637
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
Trial: NCT00650637
Drug: nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1250 mg twice a day
Trial: NCT00650637
Drug: lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
Trial: NCT00650637
Drug: loperamide
RxNorm normalized name: Loperamide
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
Trial: NCT00650637
Drug: nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nelfinavir 1250 mg twice a day
Trial: NCT00650637
Drug: lamivudine + zidovudine
RxNorm normalized name: lamivudine / zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
Trial: NCT00047554
Drug: Travoprost, 0.004% ophthalmic solution
RxNorm normalized name: Travoprost, 0.004% ophthalmic solution
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00833976
Drug: Lovaza
RxNorm normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grams per day